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Background: Alternative splicing is critical for generating complex proteomes in response to extracellular signals.
Nuclear receptors including estrogen receptor alpha (ERα) and their ligands promote alternative splicing. The
endogenous targets of ERα:estradiol (E2)-mediated alternative splicing and the influence of extracellular kinases that
phosphorylate ERα on E2-induced splicing are unknown.
Methods: MCF-7 and its anti-estrogen derivatives were used for the majority of the assays. CD44 mini gene was
used to measure the effect of E2 and AKT on alternative splicing. ExonHit array analysis was performed to identify
E2 and AKT-regulated endogenous alternatively spliced apoptosis-related genes. Quantitative reverse transcription
polymerase chain reaction was performed to verify alternative splicing. ERα binding to alternatively spliced genes
was verified by chromatin immunoprecipitation assay. Bromodeoxyuridine incorporation-ELISA and Annexin V
labeling assays were done to measure cell proliferation and apoptosis, respectively.
Results: We identified the targets of E2-induced alternative splicing and deconstructed some of the mechanisms
surrounding E2-induced splicing by combining splice array with ERα cistrome and gene expression array. E2-
induced alternatively spliced genes fall into at least two subgroups: coupled to E2-regulated transcription and ERα
binding to the gene without an effect on rate of transcription. Further, AKT, which phosphorylates both ERα and
splicing factors, influenced ERα:E2 dependent splicing in a gene-specific manner. Genes that are alternatively
spliced include FAS/CD95, FGFR2, and AXIN-1. E2 increased the expression of FGFR2 C1 isoform but reduced C3
isoform at mRNA level. E2-induced alternative splicing of FAS and FGFR2 in MCF-7 cells correlated with resistance
to FAS activation-induced apoptosis and response to keratinocyte growth factor (KGF), respectively. Resistance of
MCF-7 breast cancer cells to the anti-estrogen tamoxifen was associated with ERα-dependent overexpression of
FGFR2, whereas resistance to fulvestrant was associated with ERα-dependent isoform switching, which correlated
with altered response to KGF.
Conclusion: E2 may partly alter cellular proteome through alternative splicing uncoupled to its effects on transcription
initiation and aberration in E2-induced alternative splicing events may influence response to anti-estrogens.Background
Estradiol (E2) signaling primarily involves activation of
nuclear receptors, estrogen receptors alpha (ERα) and
beta (ERβ), which function as transcription factors that
regulate gene expression through either DNA binding or
through protein-protein interaction [1,2]. E2 signaling in* Correspondence: hnakshat@iupui.edu
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distribution, and reproduction in any mediumcells is further controlled by several post-transcriptional
modifications of ERα and ERβ including phosphoryl-
ation, acetylation, and ubiquitination. These post-
transcriptional events influence the ability of ERα to
interact with co-regulator molecules, its stability, and
localization. Kinases known to phosphorylate ERα in-
clude MAPK, IKKα, RSK, AKT/PKB, p38 kinase, PKA,
Src, cyclin A/cdk2, and cdk7 [1,3-7]. It is suggested that
changes in the phosphorylation status of the receptor
contribute to ERα dysfunction in various pathological
conditions including breast cancer.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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mechanism that permits the generation of multiple pro-
tein products from a single gene. 92-94% of human genes
undergo alternative splicing and 70-90% of these spliced
RNAs are translated into proteins [8,9]. A recent genome-
wide sequencing indicated 22,000 tissue-specific alterna-
tive splicing events [8]. Two families of splicing factors
have been identified: heterogeneous nuclear ribonucleo-
protein (hnRNP) related proteins and the serine-arginine
rich (SR) proteins [9,10]. Phosphorylation controls activity
of these proteins [9,10]. For example, RS domains of SR
proteins contain multiple copies of consensus AKT phos-
phorylation site RXRXXS and AKT controls their activity
in the nucleus and cytoplasm [11].
Defects in alternative splicing are linked to various dis-
eases including spinal muscular atrophy, neurofibroma-
tosis type 1, cystic fibrosis, breast cancer, and ovarian
cancer [12,13]. For example, alternative splicing can
change CC3, which codes for a protein with anti-
metastatic and pro-apoptotic properties, to TC3, which
codes for a protein with pro-metastatic and anti-
apoptotic properties [14]. Alternative splicing of the
transcription factor FOXP1 influences pluripotency and
differentiation of embryonic stem cells [15]. At least 15%
of human genetic diseases arise from mutations either in
consensus splice sites or in splicing silencer or enhancer
elements [12]. Cancer-associated alternative splicing,
which is regulated by FOX1, FOX2, and Nova proteins,
has been reported [16,17]. These alternative splicing
events empower cancer cells to express developmentally
regulated proteins [13]. Breast cancer subtypes show dis-
tinct splicing pattern, which may partly be related to
FOX1/FOX2 expression [16,18]. Genetic alterations in
splicing machinery is linked to myelodysplasia [19]. Re-
cent studies using bioinformatics tools including intrin-
sic disorder predictions have shown that alternative
splicing is a non-random event and often involves the
region of the protein engaged in protein-protein inter-
action [20]. Thus, loss or gain of exons through alterna-
tive splicing has major functional implications.
A clear link between steroid regulated transcription
and alternative splicing has been established [21]. At
least 25 proteins have been described to have both tran-
scription coregulator and splicing activity [22]. Proteins
involved in steroid-regulated alternative splicing events
include U2AF65-related proteins CAPERα and CAPERβ,
ASC-1, ASC-2, and CoAA [23]. Several of these mole-
cules interact directly with ERα. ERα:E2 controls
transcription-coupled alternative splicing of the first in-
tron in a gene specific manner, which impacts the rate
of co-transcriptional RNA processing [24]. However,
whether these ERα:splicing factor interactions contribute
to breast cancer subtype-enriched alternative splicing or
whether ERα:E2 induces alternative splicing uncoupledto transcription initiation activity, is yet to be deter-
mined. Additionally, there are limited number of reports
that have examined the effect of ERα phosphorylation
on alternative splicing [25]. ERα phosphorylated at S118
by MAPKs interacts with the splicing factor SF3a, a
component of U2 snRNP complex, and promotes exon
skipping [25].
We had previously shown the effects of AKT on ERα:
E2 mediated transcription, which correlated with the
phosphorylation of S167 residue of ERα [6]. Crosstalk
between ERα and AKT is likely to play a significant role
in ERα-positive breast cancer because recent genome
analyses have observed frequent activating PI3K muta-
tion in ERα-positive breast cancer, which often leads to
increased AKT activity [26,27]. Using chromatin immu-
noprecipitation coupled microarray (ChIP-on-chip) and
gene expression analysis, we demonstrated specific
effects of AKT on ERα binding to the genome and E2-
regulated transcription [28]. The effect of AKT on E2-
induced alternative splicing is unknown. To test the
effect of AKT on E2-induced alternative splicing, we first
performed CD44 minigene splicing assay and observed a
dominant effect of AKT on E2-induced alternative spli-
cing in two cell types examined. To identify endogenous
targets of E2-regulated alternative splicing and the influ-
ence of AKT on this process, we performed ExonHit
Apoptosis Splice Array analysis of ERα-positive/E2-
dependent MCF-7 breast cancer cells (MCF-7p) and the
same cell line overexpressing constitutively active AKT
(MCF-7AKT) with or without E2 treatment. Combined
analysis of splice array and other published cancer-
specific splicing data with E2-induced ERα cistrome and
gene expression arrays revealed two distinct categories
of E2-regulated alternatively spliced genes [17,28-30]. E2
induced alternative splicing of FAS/CD95 in MCF-7
cells, which correlated with resistance to FAS-activation
induced apoptosis. In addition, E2 increased the expres-
sion of fibroblast growth factor receptor 2 (FGFR2) C1
isoform without significantly altering C2 isoform levels
in MCF-7p cells. Consistent with the effect of E2 on
FGFR2 splicing, MCF-7 cells showed differential re-
sponse to keratinocyte growth factor (KGF), a ligand for
FGFR2 C1 and C2 isoforms, in the presence of E2 and
tamoxifen, an anti-estrogen. Furthermore, acquired re-
sistance to anti-estrogens tamoxifen and fulvestrant was
associated with distinct expression pattern of FGFR2
isoforms and response to KGF. Collectively, these results
suggest a role for E2 induced alternative splicing in anti-
estrogen response of breast cancer cells.
Results
AKT influences E2 induced alternative splicing
Apart from SR proteins that are phosphorylated by AKT
[11], the RS domain of splicing factors CAPERα and
Figure 1 The effect of AKT on E2-induced alternative splicing
of CD44 minigene. A) CD44 minigene splicing assay in 293 cells.
293 cells were transfected with ERE-CD44 minigene (2 μg), indicated
ERα constructs (2 μg) and either vector control pCDNA3 or pCDNA3-
CA-AKT expression vector (0.5 μg). A day after transfection, cells
were treated with ethanol or E2 for 24 hours. qRT-PCR was
performed using primers that amplify exon-included or exon-
skipped products. The ratio between exon-included and exon-
skipped products in untreated ERα and CD44-ERE transfected cells
was normalized to one and relative change in the ratio is presented.
Ratio of >1 indicates elevated exon-inclusion whereas a ratio of <1
indicates enhanced exon-skipping. B) The effect of E2 on CD44
minigene splicing in MCF-7p and MCF-7AKT cells. Cells were
transfected with ERE-CD44 minigene or HSV-CD44 minigene and
assays were performed as in A. Statistically significant differences
are indicated.
Bhat-Nakshatri et al. BMC Medical Genomics 2013, 6:21 Page 3 of 18
http://www.biomedcentral.com/1755-8794/6/21CAPERβ contain several putative AKT phosphorylation
sites [23]. Both CAPERα and CAPERβ associate with
ERα and modulate E2-dependent transcription as well as
alternative splicing [23]. Thus, AKT can potentially influ-
ence E2-induced alternative splicing by phosphorylating
multiple components of the splicing machinery. We
used the CD44 minigene splicing system containing vari-
able exons 4 and 5 (v4,5) of CD44 gene under the con-
trol of estrogen response element driven promoter
(ERE-CD44) and measured the exon inclusion/skipping
to determine the effect of AKT on E2-induced alterna-
tive splicing [21]. Two cell systems were used: 1) 293
cells requiring transfection of both the CD44 minigene
and ERα or its mutants; 2) MCF-7p and MCF-7AKT
cells transfected with the CD44 minigene. Studies in 293
cells allowed us to study phosphorylation defective mu-
tants of ERα on splicing as these cells lack ERα. Studies
in MCF-7 cells allowed us to study E2-induced splicing
in the context of E2 responsive breast cancer cells, en-
dogenous ERα and to distinguish ERE-dependent and
ERE-independent effects of E2 on alternative splicing.
We designed unique primers spanning exon-exon junc-
tions to measure exon-included and exon-skipped prod-
ucts by quantitative reverse transcription polymerase
chain reaction (qRT-PCR).
In 293 cells, only exon skipped transcripts from ERE-
CD44 minigene could be reliably measured in the ab-
sence and presence of E2 by qRT-PCR (exon-included
CT >30, exon-skipped ~25). In contrast, robust ERE-
CD44 gene activity with expression of both exon-
included (~27 CT) and exon-skipped products (~24 CT)
was observed when co-transfected with ERα (Figure 1A).
The exon-inclusion/exon-skipped ratio changed dramat-
ically in cells treated with E2 for 24 hours (range 1.7 to
6 fold in favor of included product, Figure 1A). We next
compared E2-induced alternative splicing in the pres-
ence of MAPK-phosphorylation defective (S118A) and
AKT phosphorylation defective (S167A) mutants of ERα.
ERα mutants were effective as wild type ERα in modulat-
ing alternative splicing in the presence of E2 (Figure 1A).
We then compared ERα:E2-induced alternative spli-
cing in the presence of constitutively active AKT. AKT
had a dominant effect on alternative splicing of ERE-
CD44 minigene-derived transcripts. Compared to con-
trol vector-transfected cells, exon-included/exon-skipped
transcript ratio was dramatically lower indicating the
ability of AKT to promote exon skipping and E2 failed
to reverse this effect of AKT (Figure 1A, p=0.003).
Please note that AKT did not influence transcription of
ERE-CD44 minigene in the absence of ERα, as only
exon-skipped transcripts under this transfection condi-
tion could be reliably measured (data not shown). Inter-
estingly, AKT failed to influence alternative splicing
events orchestrated by ERα phosphorylation defective
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exon skipping was completely lost in cells transfected
with S167 mutant, which is defective in AKT-mediated
phosphorylation (p=0.04; exon inc/skip ratio in wild type
vs S167A mutant ERα transfected cells with AKT).
These results indicate that AKT alters ERα:E2 induced
alternative splicing in ERα S167 phosphorylation-
dependent manner to a larger extent and S118 to a
minor extent.
We performed similar assay in parental MCF-7 cells
(MCF-7p) and cells overexpressing AKT (MCF-7AKT)
with ERE-CD44 minigene. Additionally, we included
CD44 minigene driven by herpes simplex virus
enhancer-promoter (HSV-CD44) to account for second-
ary effects of ERα:E2 on alternative splicing. As with 293
cells, E2 increased exon-inclusion/exon-skipped ratio in
cells transfected with ERE-CD44 minigene (Figure 1B).
Although alternative splicing of HSV-CD44 minigene in
E2 treated cells was different from untreated cells,
none of the differences reached statistical significance
(Figure 1B). Similarly, AKT had minimum effect on alter-
native splicing of transcripts from HSV-CD44 minigene
(Figure 1B). Taken together, these results suggest that E2
has distinct effects on alternative splicing of genes with
ERE compared to genes without ERE. In addition, AKT
has dominant effect on E2-induced alternative splicing or
confers ligand-independent splicing activity to ERα, de-
pending on the cell type.
E2 induced alternative splicing of apoptosis-related genes
To identify endogenous targets of E2-induced alternative
splicing and the potential influence of AKT in this
process, we performed microarray analysis that detects
alternative splicing of 893 genes related to apoptosis.
Array analysis was performed in quadruplicate using
RNA from MCF-7p and MCF-7AKT cells with or with-
out E2 treatment for three hours. Three hours time
point was selected to enrich for genes that are primary
targets of E2-regulated transcription and alternative spli-
cing. Data from both cell types together with or without
E2 treatment were analyzed using a more comprehensive
ANOVA model after dye bias and cell type effects were
removed. Four hundred sixty three splicing events out of
possible 10659 splice events (p<0.001) (~4%) targeting
154 genes (17% of genes) were altered in E2 treated cells
compared to untreated cells. These events were common
to both cell types. Individual cell types also showed E2-
dependent changes in splicing patterns (527 in MCF-7p
and 451 in MCF-7AKT) although statistical analysis is
not as robust as combined analysis because comparison
was only between two cell types (with and without E2
treatment). A gene list is provided as Additional file 1,
Additional file 2, Additional file 3 available online and a
partial list of the genes, few of which were verifiedfurther by qRT-PCR assays, is provided in Table 1 along
with type of splicing events and fold change in response
to E2 treatment.
Genes that undergo E2-induced alternative splicing are
enriched for ERα binding sites
E2 induced alternative splicing could involve E2-
regulated transcription-coupled splicing, ERα binding to
the gene that permits co-recruitment of splicing factors
without an effect on the rate of transcription initiation,
or a secondary event due to E2-mediated induction/re-
pression of a splicing factor(s). To test these possibilities,
we examined alternatively spliced genes for ERα binding
sites from our previous ChIP-on-chip study datasets of
MCF-7p and MCF-7AKTcells as well as a published study
involving ChIP-seq of untreated, E2-treated or tamoxifen
treated MCF-7 cells [28,29]. Among 154 genes that under-
went alternative splicing in E2 treated cells, 89 genes
contained ERα binding sites in regions within or ~20-kb
5’ or 3’ of the coding unit (Additional file 1). A 20-kb
window has previously been shown to be optimal for ERα
enhancer-promoter interactions [31]. However, we cannot
rule out the possibility of ERα binding sites located at
50–100 KB distance from 5’ and 3’ of the coding units
and ERα binding to these sites influencing gene expres-
sion or alternative splicing through looping mechanism.
We had previously shown that 299 of 837 E2-regulated
genes in MCF-7p cells and 363 of 1063 E2-regulated
genes in MCF-7AKT cells (~35%) contain ERα binding
sites [28]. In comparison, it appears that ERα binding
sites are enriched on genes that underwent E2-induced
alternative splicing (89 out of 154, ~60%, p=0.0001,
Fisher’s exact test).
ERα binding pattern to AXIN-1, Caspase 7, FGFR2,
and FAS, which were alternatively spliced upon E2 treat-
ment, is shown in Figure 2. FGFR2 displayed unique
ERα binding sites in cells overexpressing AKT and one
of these sites is located in intron 2. This intron contains
binding sites for several transcription factors and single
nucleotide polymorphism in this intron is associated
with breast cancer susceptibility, particularly postmeno-
pausal breast cancers, which are usually ERα-positive
[32-34]. Although our ChIP-on-chip did not identify
ERα binding sites around FAS, ChIP-seq data from the
other study [29] showed an ERα binding site ~40 kb up-
stream of the transcription start site. We performed
ChIP assay with ERα antibody followed by qPCR to con-
firm ERα binding to select binding sites of the above
genes (Figure 3A). Although assays were performed at
three time points after E2 treatment (one, two, and four
hours after E2 treatment), time points that showed sig-
nificant ERα binding differences between untreated and
E2 treated conditions are shown in the figure. With the
exception of FAS, statistically significant increase in ERα
Table 1 Selected E2-induced splicing events
Gene name Reference Variant Splicing
event
Long
form
p value Fold change
with E2
Caspase 7, apoptosis-related cysteine protease (CASP7),
transcript variant beta,
NM_033340 BM459840 ASA R 0.000 2.01
BG339524 ES R 0.000 2.20
BX458514 ES R 0.000 1.96
AU131461 ASD R 0.000 2.21
BX443602 ASD V 0.000 2.18
Axin 1 (AXIN1), transcript variant 1 NM_003502 AA954457 ES R 0.000 1.48
BU500157 ES R 0.000 1.48
Cyclin E1 (CCNE1), transcript variant 1 NM_001238 BG395682 ES R 0.000 1.41
CR601172 IR V 0.000 1.57
BE887210 ES R 0.001 1.41
Homeodomain interacting protein kinase 2 (HIPK2) NM_022740 AF326592 ASA R 0.000 1.36
Tumor necrosis factor receptor superfamily, member 12A
(TNFRSF12A, FN14)
NM_016639 BC064377 ES R 0.000 −1.4
Tumor necrosis factor receptor superfamily, member 10A
(TNFRSF10A)
NM_003844 BI029612 ASD R 0.001 −2.01
Inhibitor of DNA binding 1, dominant negative helix-loop-helix
protein (ID1), transcript variant 2
NM_181353 AI767705 PIED R 0.000 −2.52
BP261920 PIED R 0.000 −2.71
Tumor necrosis factor receptor superfamily, member 6 (TNFRSF6),
transcript variant 1 (FAS)
NM_000043 NM_152876 ES R 0.000 1.14
Tumor necrosis factor receptor superfamily, member 6 (TNFRSF6),
transcript variant 1 (FAS)
NM_000043 NM_152874 ES R 0.001 −1.36
Ubiquitin-activating enzyme E1C (UBA3 homolog, yeast) (UBE1C),
transcript variant 1
NM_003968 AV716795 ASA R 0.000 3.85
Reference and variant transcripts with accession number in the array are shown. Longer version of the transcript in the array (reference or the variant) is also
indicated. Positive number in fold change column indicates E2-induced splicing generating higher levels of the variant whereas negative number indicates
repression of splicing event leading to generation of the variant. ASA, alternative splice acceptor; ASD; Alternative splice donor; ES, exon skipping; IR, intron
retention; PEID, partial internal exon deletion. Additional splicing events including novel exons (NE) are in Additional file 1, Additional file 2, Additional file 3.
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treatment was observed in MCF-7p, MCF-7AKT, or
both cell types. E2 had distinct effect on ERα binding to
FAS gene in MCF-7p and MCF-7AKT cells. Unliganded
ERα bound to previously identified ChIP-seq region in
FAS gene in MCF-7p cells, which was reduced upon E2
treatment. However, in MCF-7AKT cells, E2 increased
ERα binding, which correlated with repression of E2-
regulated expression of total FAS transcripts in these
cells (see below). ChIP with control IgG did not display
any E2-dependent increase in amplification of ERα bind-
ing regions (data not shown). Taken together, the results
presented above demonstrate a correlation between ERα
binding to genes whose transcripts undergo alternative
splicing in response to E2 treatment.
We used two resources to determine whether E2-
induced alternative splicing is coupled to ERα binding as
well as changes in overall rate of transcription. First, we
determined the effect of E2 on overall mRNA levels of
alternatively spliced genes with ERα binding sites in
MCF-7p or MCF-7AKT cells using gene expression array
data from same cells treated with E2 for four hours [28].Among 89 alternatively spliced genes with ERα binding
sites, E2 induced the expression of eight genes but re-
pressed the expression of two genes in MCF-7p cells.
In MCF-7AKT cells, E2 increased the expression of 12
genes but repressed the expression of four genes
(Additional file 1). Therefore, ~80% of genes with ERα
binding sites undergo alternative splicing upon E2 treat-
ment without changing overall levels of transcription. The
second set of data derived from the publicly available data-
base (www.nursa.org/gems/) was used to independently
verify this possibility. This database contains gene expres-
sion meta-signature of MCF-7 cells treated with E2 for
three hours and 24 hours, which permitted us to meas-
ure early and late effects of E2 on overall transcription
of alternatively spliced genes [30]. Among 89 genes
with ERα binding sites, 18 genes were early-response
inducible genes (3–4 hours) whereas 15 genes were
late-response inducible genes (24 hours) with q-value
of <0.05 (Additional file 1, Additional file 4). 16 and 22
genes were repressed at early and late time points, re-
spectively. Remaining genes with ERα binding sites
(60%) underwent alternative splicing without an effect
Figure 2 ERα binding pattern to alternatively spliced genes in response to E2 treatment. ChIP-on-chip data of MCF-7p and MCF-7AKT cells
and/or ChIP-seq of MCF-7 cells with or without E2 or tamoxifen treatment reveal ERα binding sites within or around alternatively spliced genes.
Relative position of genes on respective chromosomes along with ERα binding site detected in treated cells (black bar) are shown. Black arrow
indicates direction of the gene. Asterisk indicates ERα binding sites verified by ChIP-qPCR.
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alternatively spliced genes without ERα binding sites,
13 and 19 genes were early and late E2 induced genes,
respectively, whereas four and 10 were early and late
repressed genes, respectively. Based on these two inde-
pendent analyses, we conclude that E2 induced alterna-
tive splicing need not have to be coupled to the effects
of E2 on the rate of transcription initiation. In fact, E2
had no effect on transcription of the majority of genes
(85 out of 154 were unaffected at the level of tran-
scripts) that underwent E2-regulated alternative spli-
cing with or without ERα binding sites.
E2 regulated expression of splicing factors
Since ~40% of genes lacking ERα binding sites within
20 kb of 5’ and 3’ ends of the coding unit underwent E2dependent alternative splicing, we examined the effect of
E2 on the expression of genes of the alternative splicing
machinery including those linked to cancer. First, we an-
alyzed ChIP-on-chip for ERα binding and gene expres-
sion array data of E2 treated MCF-7p and MCF-7AKT
cells for E2-regulated expression of splicing factors [28]
and observed E2-dependent increase in the SRSF7 (also
called 9G8) by more than 2-fold. Indeed, E2 increased
the expression of SRSF7 in both MCF-7p and MCF-
7AKT cells by more than 2-fold, despite lacking ERα
binding sites based on ChIP-on-Chip and ChIP-seq data
(Figure 3B). Therefore, SRSF7 may contribute to E2-
regulated alternative splicing of genes without ERα bind-
ing sites. FOX2 (also called RBM9) downregulation is
responsible for cancer-associated alternative splicing
[16]. However, FOX2 gene lacks ERα binding sites and
Figure 3 Verification of ERα binding to alternatively spliced genes. A) ChIP-qPCR was used to confirm ERα binding to genomic regions of
AXIN-1, Caspase 7, FGFR2, and FAS genes. Relative enrichment of ERα binding upon E2 treatment is shown (average and standard error of the
mean). Data from one hour (AXIN-1 and FGFR2), two hours (Caspase 7), and four hours (FAS) after E2 treatment are shown. Asterisks indicate
significant enrichment or loss of binding (p<0.02) upon E2 treatment. B) E2 increases SRSF7 expression in both MCF-7p and MCF-7AKT cells. Mean ±SE
is shown. *p<0.05, untreated versus E2 treated. The chromosomal region encompassing SRSF7 gene lacks ERα binding sites based on our ChiP-on-chip
as well as ChIP-seq data published by others (top).
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7AKT cells [28]. Genome-wide RNAi screen for genes
involved in alternative splicing of apoptosis-related genes
revealed ASF/SF2/SRSF1 as the main splicing factor that
regulates apoptosis [35]. The regulatory regions of SF2contain an ERα binding site; however, E2 did not alter
the expression of this gene in both MCF-7p and MCF-
7AKT cells. The regulatory regions of Polypyrimidine
Tract Binding protein 1 (PTB), another cancer-associated
splicing factor [13], bind to ERα in tamoxifen but not E2
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24 hours. Thus, PTB is less likely to be a major player in
E2-induced alternative splicing. The regulatory regions of
SRp20, another splicing factor overexpressed in cancer
[36], contain ERα binding sites and SRp20 is induced by
E2 at transcript level (1.36-fold, q value <0.01). However,
we did not observe elevated SRp20 protein levels in cells
treated with E2 compared to untreated cells possibly due
to higher abundance and stability of the protein (data
not shown). Furthermore, analysis of more than 20
known splicing factors did not reveal significant effects
of E2 on their expression [37,38]. Thus, SRSF7 is the
only documented E2-inducible splicing factor, which
may cause alternative splicing as a secondary event in
E2 treated cells.
Characterization of E2-induced alternative splicing at
mRNA level
A schematic view of some of the genes that underwent
alternative splicing in response to E2 treatment is given
in Figure 4A. Alternative splicing pattern of the FGFR2
C-terminus is also shown. FGFR2 was included in this
analysis because it is one among 19 genes that undergo
breast cancer-specific alternative splicing, which results
in proteins with distinct functional domains [17]. To
visualize and measure splice variants, we employed qRT-
PCR using primer sets that measure wild type or isoform
mRNA levels. We selected AXIN-1, FAS, and FGFR2 for
further analysis because of their known role in breast
cancer and apoptosis.
AXIN-1a and AXIN-1b showed distinct expression
pattern in MCF-7p and MCF-7AKT cells. In MCF-7p
cells, E2 increased the expression of both AXIN-1a and
AXIN-1b although there was a difference in the expres-
sion levels of these isoforms at given time after E2 treat-
ment (Figure 4B). Basal AXIN-1a but not AXIN-1b
levels were lower in MCF-7AKT cells compared to
MCF-7p cells (p=0.006) suggesting the ability of AKT to
alter AXIN-1 splicing independent of ERα and E2. Con-
sequently, overall levels of AXIN-1a but not AXIN-1b
were lower in E2 treated MCF-7AKT cells compared to
MCF-7p cells. AXIN-1b lacks exon-8, which codes for a
30 amino acid region containing a putative casein kinase
I phosphorylation site, oligomerization site, and two po-
tential nuclear export signals [39].
Several isoforms of FAS have been characterized [40].
FAS lacking exon 6, which is a more frequent event in
cancer, yields a soluble FAS protein with anti-apoptotic
activity [13,40]. ExonHit array experiments identified
E2-inducible expression of an isoform lacking exons 3,
4, and 6 (NM_152876) but repression of another isoform
lacking both exons 4 and 7 (NM_152874) in MCF-7p
cells (Table 1 and Additional file 2). We designed mul-
tiple qRT-PCR primers to measure the levels of totalFAS transcripts (primers spanning exon 9) and splice
variants alone. Only primers spanning total FAS and the
splice variant lacking exons 3 and 4 (forward primer
designed to exon 2 and 5 junction and reverse primer
spanning exon 6) gave reproducible results. E2 did not
change the levels of total FAS transcripts but signifi-
cantly increased the levels of the splice variant lacking
exons 3 and 4 in MCF-7p cells (Figure 4C) (please see
Figure 5 below for even higher induction of the splice
variant). E2 decreased the levels of full length but not
the splice variant in MCF-7AKT cells after one-hour
treatment suggesting a dominant effect of AKT in
redirecting ERα to suppress total FAS.
Alternative splicing of FGFR2 generates epithelial cell
specific FGFR2 IIIb and mesenchymal cell specific
FGFR2 IIIc isoforms [32]. Overall, alternative splicing
generates at least 11 splice variants of FGFR2. The C-
terminus of FGFR2 IIIb undergoes further alternative
splicing to generate constitutively active (C3) and
ligand-dependent (C1 and C2) receptors [41-43]. We
generated primers that can specifically measure the
levels of C1+C2, C2, or C3 transcripts by qRT-PCR and
determined the effect of E2 on expression levels of each
isoforms in MCF-7p and MCF-7AKT cells. Based on the
CT values, C1+C2 transcript is the predominant FGFR2
(~20 CT value) compared to C2 (~26 CT value) or C3
(~29 CT value) in both cell types. RT-PCR assay also
confirmed relative abundance of C1 and C2 transcripts
compared to C3 transcripts (data not shown). In MCF-
7p cells, E2 increased C1+C2 but not C2 transcript to a
significant level (p=0.0001, Figure 4D). In contrast, C3
levels were significantly reduced in MCF-7p cells treated
with E2 for one hour (p=0.004). C1 levels remain signifi-
cantly higher compared to C3 levels after three hours of
E2 treatment (p=0.0089). The basal C1+C2 was higher
in MCF-7AKT cells compared to MCF-7p cells (p=0.05),
while the levels of C2 were similar in MCF-7p and
MCF-7AKT cells (Figure 4D). In addition, E2 failed to
repress C3 levels in MCF-7AKT cells. These effects of
AKT on E2-induced splicing of endogenous genes are
consistent with the results obtained in transient assays
with ERE-CD44 minigene where AKT overexpression
recapitulated some of the splicing events that occur in
E2 treated cells (Figure 1B). Since AKT decreased the
level of specific splice variant in some cases (AXIN-1a
for example) but increased splice variants in other in-
stances (FGFR C1+C2, for example), the effects of AKT
on alternative splicing of E2-regulated genes is gene-
specific but not global. We emphasize that the extent of
E2- or AKT-mediated changes in alternative splicing of
endogenous genes shown above (30 to 70%) is similar to
changes in alternative splicing observed during important
biological processes such as embryonic stem cell differen-
tiation (<36% change in FOXP1 alternative splicing) [15].
Figure 4 E2-induced alternative splicing of endogenous genes. A) Partial exon-intron structure of genes that were alternatively spliced upon
E2 treatment. Exon-intron structure of wild type and spliced variants are shown. B) qRT-PCR analyses of AXIN-1a and AXIN-1b in untreated and E2
treated MCF-7p and MCF-7AKT cells. Statistically significant increase in AXIN-1a and AXIN-1b in E2 treated cells compared to untreated cells is
indicated (p<0.05). Down-regulation of AXIN-1a expression in MCF-7AKT cells compared to MCF-7p cells is indicated (**p=0.04). C) E2 increases
the levels of Δ3,4 FAS but not total FAS. qRT-PCR was performed using primers that amplify the common exon 9 (for total FAS) or spanning
exons 2 and 5 junction and exon 6. *p<0.02 untreated versus E2 treated condition. D) The effect of E2 and AKT on alternative splicing of FGFR2.
E2 increased the expression of C1 isoform (p=0.0001) but reduced C3 levels in MCF-7p cells (p=0.004). Basal FGFR2 C1 levels were elevated in
MCF-7AKT cells compared to MCF-7p cells (p=0.05).
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To further confirm E2-induced alternative splicing of
above genes leads to measurable expression of distinct
protein species, we performed western blotting. These
studies were not intended to show a direct correlation
between alternatively spliced mRNA and translation of
the specific spliced mRNA into a protein. Instead, thepurpose was to show that the alternative splicing creates
translatable mRNAs. Indeed, E2 treated cells showed a
faster migrating FAS protein of ~38 kDa in MCF-7p
cells and the basal level of this faster migrating protein
was constantly higher in MCF-7AKT cells (Figure 5A).
We do note that there were experimental variations in
the number of faster migrating bands of FAS in E2
Figure 5 E2-induced changes in FAS and FGFR2 proteins. A) MCF-7p and MCF-7AKT cells express FAS proteins of different mobility with or
without E2 treatment. Cells were treated with E2 for indicated time (in hours) and cell lysates were subjected to western blotting. B) Dominant-
negative AKT (KD-AKT) inhibits E2-induced alternative splicing of FAS as evident from qRT-PCR assays. *p<0.03, total vs isoform at 3 and 6 hour E2
treated condition in control cells. C) The effect of E2 on FGFR2 protein in MCF-7p and MCF-7AKT cells. *p=0.0004 untreated vs six hour E2 treated
MCF-7p cells (for faster migrating FGFR2). *p=0.03 untreated MCF-7p versus untreated MCF-7AKT cells. Two exposures of FGFR2 blot are shown.
D) ERα is essential for E2 regulated FGFR2 expression. Cells were treated with control luciferase siRNA (Luci) or ERα siRNA. After three days of
siRNA transfection, cells were additionally treated with ethanol or E2 for 24 hours. Two exposures of FGFR2 and ERα blots are shown.
Bhat-Nakshatri et al. BMC Medical Genomics 2013, 6:21 Page 10 of 18
http://www.biomedcentral.com/1755-8794/6/21treated cells as well as detection by Western blot ana-
lysis possibly reflecting experimental and/or cell lysis
conditions altering the stability of the isoforms (data not
shown). In addition, since FAS undergoes multiple alter-
native splicing [40], it is impossible to assign a splice
variant transcript to a protein species.
We further characterized the role of AKT in E2-
induced alternative splicing of FAS by generating MCF-7
cells overexpressing dominant negative AKT (KD-AKT)
[6]. While E2 increased alternatively spliced FAS in par-
ental cells, this effect of E2 was completely abolished in
cells overexpressing KD-AKT (Figure 5B).We observed an effect of E2 on two FGFR2 protein
species in MCF-7p cells (Figure 5C). One is an abun-
dantly expressed faster migrating protein, which was in-
duced by E2 (indicated by an arrow). The basal level of
this FGFR2 protein was significantly higher in MCF-
7AKT cells compared to MCF-7p cells. Another minor
slower migrating FGFR2 protein was detected in both
cells and levels of this protein declined initially with E2
treatment but restored/increased after 24 hours (indi-
cated by an arrow with star). To determine the require-
ment of ERα for the expression of these isoforms of
FGFR2, we knocked down ERα using siRNA. ERα siRNA
Bhat-Nakshatri et al. BMC Medical Genomics 2013, 6:21 Page 11 of 18
http://www.biomedcentral.com/1755-8794/6/21significantly reduced basal and E2-inducible expression
of both FGFR2 protein species in MCF-7AKT cells
(Figure 5D). We are unsure why ERα siRNA had lower
effect on FGFR2 expression in MCF-7p cells. Residual
ERα in siRNA treated cells may be sufficient for FGFR2
expression in these cells.
Anti-estrogen resistance is associated with differential
FGFR2 C isoform expression
We next investigated whether resistance to anti-
estrogens is associated with altered expression of FGFR2
isoforms. For this purpose, we used a single cell-derived
clone of MCF-7 cell line that has acquired resistance to
tamoxifen (OHTR) or fulvestrant (Ful-R). MCF-7 and
OHTR cells express similar levels of ERα, whereas Ful-R
cells express very little ERα protein compared to other
cell types [44]. Western blot analysis was performed to
determine whether FGFR2 isoforms are differentially
expressed in these cell lines. Similar to results presented
in Figure 5, two FGFR2 proteins, one abundant faster
migrating species and one minor slower migrating spe-
cies were detected in these cell lines and E2-dependency
varied between cell lines (Figure 6A). The basal expres-
sion of the faster migrating band was significantly higher
in OHTR cells compared to parental cells and was not
influenced by E2 in this cell line. Note that OHTR cells
do not express slower migrating FGFR2 indicating iso-
form switching in resistant cells. In contrast, the minor
slower migrating FGFR2 was E2-inducible in the paren-
tal cell line but constitutively elevated in Ful-R cells.
Therefore, anti-estrogen resistance is associated with
alternative splicing of FGFR2 and corresponding change
in protein levels. We used siRNA against ERα to deter-
mine which among the FGFR2 isoform expression
requires ERα. ERα siRNA completely abolished the E2-
inducible expression of slower migrating minor FGFR2
in parental cells and even in Ful-R cells, which has lower
levels of ERα compared to other cell lines (Figure 6B).
Therefore, elevated basal expression of slower migrating
FGFR2 in Ful-R cells is dependent on residual ERα
levels. Basal expression of faster migrating FGFR2 in
OHTR cells was also ERα dependent. For unknown rea-
son, we were only able to knockdown <50% of ERα in
this single cell-derived MCF-7 clone and OHTR cells.
Despite discrepancy with respect to ERα dependency of
faster migrating FGFR2 in parental MCF-7 cells and
clonal MCF-7 (Figure 5 and Figure 6), results support
the conclusion that slower migrating FGFR2 is E2 and/
or ERα dependent across cell lines.
To confirm that overexpression of FGFR2 protein in
OHTR cells and lower expression in Ful-R cells correlate
with mRNA changes, we performed qRT-PCR analysis
(Figure 6C). OHTR cells expressed higher levels of all three
FGFR2 isoforms tested, whereas Ful-R cells expressedlower levels of all three isoforms tested compared to
parental cells. Therefore, FGFR2 protein changes in anti-
estrogen resistant cells correlate changes in mRNAs but it
is difficult to assign these changes to specific isoforms.
KGF serves as a ligand to FGFR2 C1 and C2 isoforms,
whereas C3 is active independent of ligand [41,42]. Since
OHTR cells expressed higher levels of FGFR2 protein
compared to parental cells and Flu-R cells expressed dif-
ferent levels of FGFR2 isoforms compared to parental or
OHTR cells, it is possible that anti-estrogen resistant
cells respond differently to KGF compared to parental
cells. While KGF stimulated the growth of parental cells,
OHTR cells displayed elevated basal proliferation, which
was unaffected upon KGF stimulation. Ful-R cells also
displayed elevated basal proliferation and were unre-
sponsive to KGF stimulation (Figure 6D). These results
indicate that resistance to anti-estrogens is associated
with differential FGFR2 isoform expression and response
to KGF.
FGFR2 C2 and FGFR2 C3 alter basal proliferation rate and
consequently response to E2
Since FGFR2 C2 isoform expression was not E2 respon-
sive, whereas C3 expression was repressed by E2, we
examined how constitutive overexpression of these
isoforms alters cellular response to E2 and tamoxifen.
Expression levels of overexpressed FGFR2 isoforms are
shown in Figure 6E. Both FGFR2 C2 and C3
overexpressing cells showed elevated basal proliferation
compared to parental cells with retrovirus vector alone
and E2 further stimulated proliferation (Figure 6F). Simi-
lar to parental cells, tamoxifen reduced E2-stimulated
proliferation of FGFR2 C2 and C3 overexpressing cells.
These results suggest that FGFR2 C2 and C3
overexpression provides proliferative advantage mimick-
ing increased proliferation observed with anti-estrogen
resistant cells compared to parental cells. Overall, prolif-
eration rate of C2 or C3 overexpressing cells was much
higher than parental cells (p<0.0002). Proliferation rate
of FGFR2 C2 overexpressing cells remained higher than
parental cells when cells were treated with E2 plus tam-
oxifen. Thus, individual isoforms of FGFR2 can influence
basal proliferation and consequently response to E2 and
anti-estrogens. Since it is difficult to knockdown individ-
ual isoforms of FGFR2 due to limited sequence diver-
gence between isoforms and to develop isoform specific
inhibitors, our observation linking specific isoforms of
FGFR2 to anti-estrogen response remains correlative.
Estrogen-induced alternative splicing of FAS and FGFR2
correlates with resistance to FAS activation-induced cell
death and KGF-induced proliferation, respectively
To determine the consequences of E2-induced alterna-
tive splicing of FAS on sensitivity to FAS activation-
Figure 6 FGFR2 isoforms and anti-estrogen resistance. A) FGFR2 proteins in untreated and E2 treated (24 hours) MCF-7, OHTR, and Ful-R
cells. Three cell types express different levels of FGFR2 proteins. B) FGFR2 C1, C2, and C3 mRNA levels in MCF-7, OHTR, and Ful-R cells. *, ** p<0.05
compared to parental MCF-7 cells. C) ERα is essential for the expression of slower migrating FGFR2 protein. siRNA experiments were performed as in
Figure 5. Two exposures of ERα blot are shown to demonstrate the presence of residual ERα in Flu-R cells. D) The effect of KGF on proliferation of
MCF-7, OHTR, and Ful-R cells. Cells were treated with KGF for six days and cell proliferation was measured using BrDU-ELISA. KGF stimulated
proliferation of MCF-7 cells but not OHTR or Ful-R cells (*p=0.0001). OHTR and Ful-R cells displayed elevated basal proliferation compared to MCF-7
cells (**p=0.0001). E) Western blot analysis shows FGFR2 expression in vector control or FGFR2 C2 or C3 infected cells. F) E2 and tamoxifen sensitivity
of FGFR2 C2 and C3 overexpressing cells. Cells were treated with E2 (10-10 M), 4-hydoxy tamoxifen (1 μM) or both for six days and cell proliferation was
measured using BrDU-ELISA. Basal proliferation of FGFR2 C2 and C3 overexpressing cells was significantly higher compared to parental cells. E2
stimulated proliferation of all three-cell types.
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cells with an antibody that triggers FAS-dependent
apoptosis. MCF-7p and MCF-7AKT cells maintained in
charcoal-stripped serum containing media displayed
basal apoptosis, which was reduced upon E2-treatment
(Figure 7A). FAS antibody treatment increased apoptosis
in both cell types, which was more pronounced in MCF-
7p compared to MCF-7AKT cells. Lower sensitivity of
MCF-7AKT cells compared to MCF-7p cells is consist-
ent with diminished basal full-length FAS protein levels
in these cells. This observation is also consistent withFigure 7 Association between E2-induced alternative splicing of FAS
respectively. A) The effect of E2 on FAS-activation induced apoptosis. Cell
co-treatment with E2 for 48 hours. Annexin V labeling followed by flow cyt
data from three experiments are shown. B) KGF partially overcomes the eff
were treated with E2 (0.1 nM), 4-hydroxy tamoxifen (0.25 nM), KGF (20 ng/m
measure the rate of cell proliferation. Results are from a representative of th
Reproducibly statistically significant results are described in the text.the known anti-apoptotic function of AKT [45]. E2 sub-
stantially reduced the FAS-antibody triggered apoptosis
in both cell types. Thus, E2-induced alternative splicing
of FAS may have an impact on FAS-activation mediated
cell death.
We next examined the effect of KGF on growth of
MCF-7p and MCF-7AKT cells in the presence of E2, low
dose 4-hydroxy-tamoxifen, or both. (Figure 7B). At this
dose, tamoxifen reduced only E2-induced growth of
both cell types. KGF increased the proliferation of both
cell types (untreated versus KGF treated p=0.006 forand FGFR2, and cellular response to apoptosis and proliferation,
s were treated with 50 ng/ml FAS-activating antibody with or without
ometry was used to measure apoptosis. Representative flow cytometry
ect of tamoxifen on E2-induced cell proliferation. Cells in 96-well plate
l) or indicated combinations for 48 hours. BrDU-ELISA was used to
ree experiments with six wells per treatment in each experiment.
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treated MCF-7p cells but not MCF-7AKT cells showed
significant increase in proliferation (MCF-7p cells E2
versus E2 plus KGF, p=0.015). The proliferation rate of
MCF-7p cells treated with a combination of KGF, E2,
and tamoxifen were higher than untreated, tamoxifen-
treated, and tamoxifen plus E2 treated cells (p<0.0002),
indicating the ability of activated FGFR2 to overcome
the effects of tamoxifen on E2-induced proliferation.
Consistent with our previous results [6], MCF-7AKT
cells treated with E2 plus tamoxifen were more prolifera-
tive than MCF-7p cells treated with E2 plus tamoxifen
(p=0.021) and KGF did not additionally increase the pro-
liferation of E2 plus tamoxifen treated MCF-7AKT cells.
These results indicate E2-mediated increase in FGFR2
C1 isoform provides additional receptors for KGF
allowing higher proliferation rate as well as diminished
response to tamoxifen.
Discussion
Role and regulation of ERα in E2-regulated alternative
splicing
Extracellular signal-dependent alternative splicing is a
major mechanism responsible for diversification of mo-
lecular repertoire by affecting several cellular functions
including apoptosis, stem cell maintenance and differen-
tiation, cell migration, and invasion [9,46,47]. Apart from
growth factor-induced signaling pathways, which can
modulate alternative splicing through phosphorylation of
splicing factors, steroid hormones couple transcription
to splicing by recruiting splicing factors to the transcrip-
tion machinery through nuclear receptors [21]. It is not
known whether steroid hormones increase splicing effi-
ciency without altering the rate of transcription. Genome
wide analysis of ERα binding patterns has revealed that
the largest fraction (38%) of ERα binding sites is mapped
to intragenic regions including introns and several of
these interactions have previously been described as un-
productive [48-50]. It is possible that the primary func-
tion of ERα bound to intragenic regions is to recruit
splicing factors to modulate alternative splicing without
changing overall transcription rates. ERα and associated
co-factors recruited to these sites may induce specific
histone modifications that favor exon skipping or exon
inclusion [51].
It is interesting that several of the genes that under-
went E2-regulated alternative splicing have intragenic
ERα binding sites (Figure 2). In fact, ~60% of the genes
that bound to ERα and underwent alternative splicing
without change in the rate of transcription (Additional
file 1 and Additional file 4) may utilize ERα for local
recruitment of histone modifying enzymes that favor al-
ternative splicing events. We also observed both E2-
induced and repressed genes undergoing alternativesplicing. Thus, E2-induced alternative splicing is unre-
lated to rate of transcription but could be related to the
ability of E2:ERα to recruit histone-modifying enzymes
along the path of transcript elongation. In this context,
rate of transcription elongation has greater influence on
alternative splicing [51]. Alternatively, E2 inducible spli-
cing factors such as SRSF7 is responsible for E2-induced
alternative splicing without an effect of E2 on rate of
transcription. SRSF7 has previously been shown to in-
crease alternative splicing of exon 6 of BRCA1 variant
with exon skipping mutation c.231G>T [52]. Therefore,
genetic variation, in addition to SRSF7 induction, may
contribute to diversity in E2-regulated alternative spli-
cing events.
A large number of splicing factors associate with ERα
including splicing factors of the hnRNPA1 complex
(CoAA for example) and SR proteins (CAPER and SF2)
[22,23,53]. Select RNA-recognition motifs (RRMs)
present in these splicing factors are involved in inter-
action with ERα, transactivation, and splicing [53,54]. RS
domains, which are present in SR proteins including
SRSF7, are heavily phosphorylated by AKT [11]. Our re-
sults suggest that AKT has dominant but gene-specific
effect on E2-induced alternative splicing. Activating mu-
tation of AKT is mostly observed in ERα-positive breast
cancer [26]. Therefore, it is possible that the dominant
gene-specific effect of AKT on ERα:E2 induced alterna-
tive splicing is one of many functions of AKT that con-
tribute to tumorigenesis. However, mechanistic aspect of
ERα:E2 induced alternative splicing, which is additionally
controlled by AKT, remain to be investigated.
E2-regulated alternative splicing and cell signaling
To date, the specific contribution of ERα:E2-induced, -
repressed, and -alternatively spliced genes on breast
tumorigenesis has not been established. However, our
analyses show that ERα:E2 contributes to breast cancer-
enriched alternative splicing. Cancer cells often use al-
ternative splicing as a mechanism to produce proteins
that promote growth and survival [13]. Genes that we
have characterized in this study for E2-regulated alterna-
tive splicing provide glimpse of how these alternative-
spliced products may alter signal transduction as well as
response to therapy (Figures 6 and 7).
FGFR2 alternative splicing is highly relevant as poly-
morphism in intron 2, which may lead to increased ex-
pression, is associated with higher risk of breast cancer
[32,33]. In this context, we observed overexpression of
FGFR2 in tamoxifen-resistant cells. FGFR2 C1 and C2
isoforms are ligand dependent receptors that bind to
KGF, whereas the C3 isoform is constitutively active
[42]. C1 isoform is expressed in normal mammary epi-
thelial cells, whereas C3 expression is restricted to
transformed cells [42]. Although all three isoforms have
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and imparts invasive capabilities [41,55]. Our results
showed that E2 increases the expression of C1 isoform
but reduces C3 expression in parental cells. AKT in-
creased C1 in ERα-dependent but E2-independent man-
ner as siRNA against ERα reduced FGFR2 levels at both
basal and E2 treated condition (Figure 5). FGFR2
overexpression and isoform switching are involved in
anti-estrogen resistance as FGFR2 protein species in
tamoxifen and fulvestrant resistant cells are different
from each other as well as from parental cells. At
present, there are no assays or reagents to verify whether
FGFR2 proteins differentially expressed in anti-estrogen
resistant cells correspond to C1, C2, or C3 isoforms
characterized in this study. Presence of at least 11 differ-
ent FGFR2 isoforms, most affecting open reading
frames, complicates interpretation. Nonetheless, data
presented in this study suggest FGFR2 is a target for
overcoming anti-estrogen resistance in breast cancer.
FGFRs (both 1 and 2) are upregulated in breast cancer
and cooperate with Wnt signaling to enhance mammary
tumorigenesis [56]. Whether E2-induced splicing of
FGFR2 and AXIN-1 (a negative regulator of Wnt) con-
tributes to this cooperative tumorigenesis and how aber-
rant splicing events contribute to response to therapy
remains to be investigated.
Alternative splicing of FAS is linked to apoptosis re-
sistance in cancer [40]. FAS itself regulates alternative
splicing through dephosphorylation of SR proteins [57].
FAS-activated signaling is essential for bone protective
function of E2 as it is responsible for E2-induced apop-
tosis of osteoclasts [58,59]. Paradoxically, FAS is essen-
tial in tumor growth, although whether this function of
FAS is dependent on a particular isoform is unknown
[60]. The effect of E2 in preventing FAS-activation
dependent apoptosis in breast cancer cells will have an
impact on therapeutic response as active Fas/FasL can
amplify the pro-apoptotic effects of chemotherapeutic
drugs.
Conclusions
This study identified E2 regulated alternative splicing of
genes involved in apoptosis and breast epithelial cell
transformation. E2-regulated splicing may be coupled to
ERα:E2 regulated transcription or independent of tran-
scription but involves ERα:E2 mediated recruitment of
splicing factors/histone-modifying enzymes and/or E2
regulated expression of splicing factors such as SRSF7.
Extracellular signal activated kinases such as AKT, which
are often activated/overexpressed in therapy resistant
breast cancers, may additionally alter these functions of
E2 to modify the course of the disease. Furthermore,
FGFR2 overexpression and/or alternative splicing may
be associated with anti-estrogen resistance.Methods
Plasmid constructs, reagents, and antibodies
CD44 minigene constructs have been described previ-
ously [21]. The constitutively active AKT (CA-AKT) and
the dominant negative AKT (KD-AKT) have been de-
scribed previously [6] and retrovirus constructs with
CA-AKT and KD-AKT sequences were generated using
the bicistronicpQCXIP vector (Clontech) [28]. FGFR2
C2 and C3 cDNAs in pBabe retrovirus vector were a
generous gift from Dr. Channing Der and have been de-
scribed previously [41]. ER ab10 (Neomarker, Fremont,
CA) and ERα sc-543 (Santa Cruz Biotechnology, Santa
Cruz, CA) were used in combination for ChIP assay.
The antibody against FGFR2 was from Santa Cruz
Biotechnology. Antibody against FAS (clone CH11)
was from Millipore (Temecula, CA). Keratinocyte
Growth Factor (KGF) was purchased from R&D Systems
(Minneapolis, MN).
Cell culture, retrovirus generation, and transfection
MCF-7 cells were grown in MEM with 10% fetal calf
serum (FCS), whereas Amphophenix cells were maintained
in DMEM plus 10% FCS. Retrovirus packaging and gener-
ation of MCF-7 cells overexpressing CA-AKT, KD-AKT,
FGFR2 C2, and FGFR2 C3 have been described previously
[28]. In all studies involving E2 treatment, cells were
maintained in phenol red-free MEM plus 5% dextran char-
coal treated serum (CCS) for at least four days prior to ex-
periments and all assays were done in this media. Single
cell-derived MCF-7 clone and its tamoxifen and fulvestrant
resistant variants of MCF-7 cells have been described pre-
viously and were gift from Dr. Ken Nephew [44].
ExonHit splice array
A microarray analysis of alternative splicing events cov-
ering a possible 10659 splice events of 893 apoptosis re-
lated genes was done using the array services of ExonHit
Therapeutics, Inc. (Gaithersburg, MD). The splicing
events analyzed include alternative splice acceptor
(ASA), alternative splice donor (ASD), exon skipped
(ES), exons skipped (EsS), intron retained (IR), novel
exon (NE), novel exons (NEs), and partial internal
exon deletion (PIED). RNA from untreated or E2
treated (10-10 M for 3 hours) MCF-7p and MCF-7AKT
cells were assayed in quadruplicate and those probes
which gave difference between untreated and E2-
treated cells with a p value from the ANOVA analysis
of less than or equal to 0.001 were considered for fur-
ther analysis.
RNA isolation and quantitative reverse transcription
polymerase chain reaction (qRT-PCR)
RNA was isolated using the RNAeasy kit from Qiagen
(Valencia, CA). qRT-PCR with specific primers was
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and splice variants. All qRT-PCR reactions were done
using 2–5 independent RNA preparations. Mean and
standard error of the mean (SE) are presented in the
figures. Statistical evaluations were done using unpaired
t test (Graphpad.com). In some cases, results from
experiments that showed extreme variability were ex-
cluded. Sequences of primers used for qRT-PCR are
listed in Additional file 5.
Chromatin immunoprecipitation assay (ChIP)
ChIP-on-chip assay of MCF-7p and MCF-7AKT cells for
ERα binding site has been described previously [28].
ERα binding to select genes that were alternatively
spliced in response to E2 was verified by ChIP followed
by real time PCR (ChIP-qPCR) as described previously
[48]. The results presented are from two or more experi-
ments. Since ChIP-qPCR is a very sensitive assay with
wide experimental variability with respect to levels of
E2-induced ERα binding, results of experiments that
showed lower variability were selected for presentation.
SiRNA transfection and western blotting
siRNA against ERα and the control luciferase were pur-
chased from Dharmacon (Lafayette, CO) and transfected
into cells using lipofectamine reagent. Protein extracts
from transfected cells were prepared four days after
transfection. Whole cell lysates from cells with or with-
out E2 treatment for 24 hours were prepared in RIPA
buffer and western blotting was preformed as described
previously [61].
Cell proliferation and cell death assays
For cell proliferation, 2000 cells maintained in phenol red-
free plus 5% CCS containing media for four days were
plated in the same media in each well of a 96-well plate
overnight and then treated with indicated reagents for 2–
6 days depending on the experiment. Bromodeoxyuridine-
ELISA (EMD Chemicals, Gibbstown, NJ) was used to
measure cell proliferation. For cell death assay, cells were
plated in a 60 mm plate and treated with indicated re-
agents for 48 hours. Cell death assay was performed using
Annexin V labeling followed by flow cytometry as sug-
gested by the manufacturer (Invitrogen).
Additional files
Additional file 1: E2-induced splice events common to MCF-7p and
MCF-7AKT cells. This file describes E2-regulated splicing events common
to MCF-7p and MCF-7AKT cells. In addition, this file also indicates ERα
binding sites in the genes that undergo E2-regulated alternative splicing
as well as the effect of E2 on expression of these genes in MCF-7p and
MCF-7AKT cells. Furthermore, the early (three hours) and the late effects
(24 hours) of E2 treatment on overall transcription of genes (extracted
from NURSA website) are also shown. Longer version (LF) of thetranscript in the array [reference (R) or the variant (V)] is also indicated.
Positive number in fold change column indicates E2-induced splicing
generating higher levels of the variant whereas negative number
indicates repression of splicing event leading to generation of the
variant. ASA, alternative splice acceptor; ASD; Alternative splice donor; ES,
exon skipping; IR, intron retention; PEID, partial internal exon deletion.
Additional file 2: E2-induced splicing events observed in MCF-7p
cells. This file is similar to Additional file 1 except that splicing events
unique to MCF-7p cells are indicated.
Additional file 3: E2-induced splicing events observed in MCF-7AKT
cells. This file is similar to Additional file 1 except that splicing events
unique to MCF-7AKT cells are shown.
Additional file 4: Summary of ERα binding and E2-regulated
expression of genes described in Additional file 1.
Additional file 5: Primer sequences used for qRT-PCR analyses.
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SRSF7: Serine/arginine-rich splicing factor 7.
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